Syndax Pharmaceuticals, Inc.
NASDAQ:SNDX
19.12 (USD) • At close September 13, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 139.709 | 1.517 | 1.517 | 1.517 | 2.108 | 1.22 | 0.627 | 0 | 0 | 0 |
| Cost of Revenue
| 0.012 | 0.454 | 0.456 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| -0.012 | -0.454 | 139.253 | 1.517 | 1.517 | 1.517 | 2.108 | 1.22 | 0.627 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0.997 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 163.02 | 118.499 | 88.248 | 50.435 | 42.994 | 60.106 | 48.201 | 31.665 | 9.549 | 10.175 | 3.208 | 5.24 |
| General & Administrative Expenses
| 0 | 33.258 | 25.241 | 22.505 | 16.062 | 17.287 | 15.861 | 13.321 | 11.591 | 11.157 | 5.363 | 3.494 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 66.922 | 33.258 | 25.241 | 22.505 | 16.062 | 17.287 | 15.861 | 13.321 | 11.591 | 11.157 | 5.363 | 3.494 |
| Other Expenses
| 0 | 2.419 | -1.294 | -1.735 | 1.492 | 1.915 | 1.152 | -0.706 | -0.037 | 0.004 | -3.014 | -0.001 |
| Operating Expenses
| 229.942 | 151.757 | 113.489 | 72.94 | 59.056 | 77.393 | 64.062 | 44.986 | 21.14 | 21.332 | 8.571 | 8.734 |
| Operating Income
| -229.954 | -151.757 | 26.22 | -71.423 | -57.539 | -75.876 | -61.954 | -43.766 | -20.513 | -21.332 | -8.571 | -8.734 |
| Operating Income Ratio
| 0 | 0 | 0.188 | -47.082 | -37.929 | -50.017 | -29.39 | -35.874 | -32.716 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 20.594 | 2.419 | -1.294 | -1.735 | 1.492 | 1.915 | 1.152 | -0.706 | -2.192 | 1.793 | -4.829 | 3.442 |
| Income Before Tax
| -209.36 | -149.338 | 24.926 | -73.158 | -56.047 | -73.961 | -60.802 | -44.472 | -24.119 | -19.828 | -14.171 | -9.965 |
| Income Before Tax Ratio
| 0 | 0 | 0.178 | -48.225 | -36.946 | -48.755 | -28.843 | -36.452 | -38.467 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | -5.589 | -0.043 | -0.089 | -0.092 | 1.915 | -0.076 | -0.089 | 1.538 | -1.5 | 2.586 | 1.23 |
| Net Income
| -209.36 | -143.749 | 24.926 | -73.069 | -55.955 | -73.961 | -60.802 | -44.472 | -24.119 | -19.828 | -14.171 | -9.965 |
| Net Income Ratio
| 0 | 0 | 0.178 | -48.167 | -36.885 | -48.755 | -28.843 | -36.452 | -38.467 | 0 | 0 | 0 |
| EPS
| -2.98 | -2.37 | 0.48 | -1.77 | -1.84 | -2.92 | -2.9 | -3.04 | -1.39 | -2.07 | -1.77 | -0.14 |
| EPS Diluted
| -2.98 | -2.37 | 0.46 | -1.77 | -1.84 | -2.92 | -2.9 | -3.04 | -1.39 | -2.07 | -1.77 | -0.14 |
| EBITDA
| -229.942 | -151.757 | 26.22 | -71.423 | -57.539 | -75.876 | -61.954 | -43.766 | -20.368 | -23.106 | -6.743 | -12.143 |
| EBITDA Ratio
| 0 | 0 | 0.188 | -47.082 | -37.929 | -50.017 | -29.39 | -35.874 | -32.485 | 0 | 0 | 0 |